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ABSTRACT
We investigated whether pretransplantation immunosuppression with canine-specific rabbit antithymocyte
globulin (ATG), combined with a suboptimal dose of 1 Gy of total body irradiation (TBI), would permit
engraftment of canine dog leukocyte antigen–identical marrow. Cumulative ATG doses of 2 to 5 mg/kg
produced a T-cell depletion of 1 log in the peripheral blood and 50% in the lymph nodes. Serum levels of ATG
peaked on days 4 to 6 after initiation of therapy and became undetectable by day 13 as a result of canine
antibody responses to ATG. ATG prolonged allogeneic skin graft survival to 14 days (n  5), compared with
8 days in control dogs (P .0003). Five dogs were given marrow transplants after ATG (3.5-5 mg/kg) and 1 Gy
of TBI. Posttransplantation immunosuppression consisted of mycophenolate mofetil and cyclosporine. All
dogs showed initial engraftment, with maximum donor chimerism levels of 25%. However, only 1 dog achieved
sustained engraftment, and 4 rejected their grafts. The duration of engraftment ranged from 8 to >36 weeks
(median, 11 weeks), and this is comparable to that in 6 historical controls not given ATG (range, 3-12 weeks;
median, 10 weeks; P  .20). The total nucleated cell doses in the marrow grafts had the highest correlation
coefficient with the duration of engraftment: 0.82 (P  .09). We concluded that administering ATG before an
otherwise suboptimal conditioning dose of 1 Gy of TBI failed to secure uniform stable hematopoietic
engraftment.
© 2005 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
We have developed a nonmyeloablative regimen
or hematopoietic cell transplantation (HCT) between
og leukocyte antigen (DLA)–identical canine litter-
ates. It consists of conditioning with 2 Gy of total
ody irradiation (TBI) and a short course of postgraft-
ng immunosuppression with mycophenolate mofetil
MMF) and cyclosporine (CSP) [1]. This regimen has
een successfully translated into clinical trials for pa-
ients thought to be at high risk for toxicities from
onventional myeloablative regimens [2-4].
The major role of pretransplantation TBI in this
odel seemed to be host immunosuppression, ratherhan creation of “marrow space” for grafts to home, a
B & M Tecause successful stable allografts could also be
chieved when 4.5 Gy of irradiation to the cervical,
horacic, and upper abdominal lymph node chains was
ubstituted for 2 Gy of TBI [5]. Prompt and stable
ngraftment of donor cells was documented in nonir-
adiated marrow and lymph node spaces of recipient
ogs.
When the TBI conditioning dose was decreased to
Gy, initial uniform allogeneic engraftment was seen,
ut all dogs eventually lost their grafts, despite MMF
nd CSP; this shows a delicate immunologic balance
etween host and donor [1]. Attempts at establishing
table allografts after 1 Gy of TBI have met with
ixed success. Substituting the immunosuppressive
gent sirolimus for MMF postgrafting yielded only
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3ransient engraftment, [6] as did the pretransplanta-
ion use of the novel immunosuppressive agent
TY720, even though it caused profound peripheral
lood lymphocytopenia [7].
However, stable grafts after conditioning with
Gy of TBI were seen in most recipient dogs after
hey were “sensitized” against their marrow donors by
ntravenous (IV) injections of peripheral blood mono-
uclear cells (PBMCs), with concurrent blockage of
ostimulatory signals from B7 to CD28 by injections
f the fusion peptide CTLA4Ig [8]. This result vali-
ated the continued search for immunosuppressive
gents that were less toxic than, and could be substi-
uted for, TBI.
Antithymocyte globulin (ATG) is a mixture of
olyclonal antibodies with potent immunosuppressive
ffects [9]. ATG has been used in combination with
educed-intensity [10-12] and nonmyeloablative [13,14]
onditioning regimens for allogeneic HCT.
In this study, we asked whether rabbit anti-canine
TG, given before 1 Gy of TBI, would facilitate
table engraftment of marrow from DLA-identical
onors in recipients administered a brief course of
ostgrafting MMF and CSP. The marrow graft stud-
es were preceded by pharmacokinetic and skin graft
tudies; ATG dosing was aimed at reducing peripheral
lood CD3 T-cell counts to 10% of the baseline
alues.
ATERIALS AND METHODS
ogs
Litters of beagles and mini–mongrel crossbreeds
ere either raised at the Fred Hutchinson Cancer
esearch Center (FHCRC; Seattle, WA) or purchased
rom commercial kennels. Dogs were observed for
isease for at least 60 days before study. All dogs were
nrolled in a veterinary preventive medicine program
hat included routine anthelmintics and a standard
mmunization series against canine distemper, parvo-
irus, adenovirus type 2, parainﬂuenza virus, corona-
irus, and rabies. In addition, 2 intradermal doses of a
ustom-prepared formalin-inactivated canine papil-
oma virus vaccine were administered. Dogs weighed
rom 9.0 to 15.8 kg (median, 12.0 kg). Elevated en-
losed runs were used for housing, and dogs were
aintained in social groups wherever possible. This
tudy was approved by the Institutional Animal Care
nd Use Committee at FHCRC, which is fully accred-
ted by the Association for Assessment and Accredita-
ion of Laboratory Animal Care, International. DLA
atching was performed by using highly polymorphic
ajor histocompatibility complex–associated class I
nd class II microsatellite markers [15,16] and DLA-
RB1 sequencing [17]. d
36ntithymocyte Globulin
Canine-speciﬁc rabbit ATG was provided by
angStat Medical Corporation (Fremont, CA). It was
roduced by inoculating rabbits with canine thymo-
ytes obtained from neonates. The immunoglobulin
(Ig) fraction from the rabbit serum was isolated by
dsorption on a protein A column and cryopreserved
t70°C in a concentration of 8.39 mg/mL with a pH
f 8. ATG was thawed before use, ﬁltered through a
.2-m-pore membrane, and administered undiluted
o the study dogs, subcutaneously (SQ) in 14 and IV
n 1. No premedication was given. Endotoxin mea-
urements showed 41 endotoxin units per milliliter.
onoclonal Antibodies
Monoclonal antibodies (mAbs) speciﬁc for canine
D3 (CA17.6F9; IgG2b), [18] CD4 (CA13.1E4;
gG1), CD8 (CA9.JD3; IgG2a), [19] and CD21
CA2.1D6; IgG1) were kindly provided by Dr. Peter
oore (School of Veterinary Medicine, University of
alifornia, Davis). An antibody against canine CD34
2E9; IgG1) [20] was kindly provided by Dr. Richard
ash (FHCRC). All mAbs were produced and puriﬁed
t the Biologics Production Facilities of the FHCRC.
he primary mAbs were unconjugated (CD34 and
D21), ﬂuorescein isothiocyanate (FITC) conjugated
CD3), or biotinylated (CD4 and CD8) according to
tandard protocols. The corresponding isotype control
ntibodies were used in parallel in each case.
low Cytometry
Red blood cells were lysed by using a hemolytic
uffer containing ethylenediaminetetraacetic acid.
he white blood cells were washed with cold Hanks
uffered salt solution (HBSS) supplemented with 2%
eat-inactivated horse serum. The primary mAbs
ere added (4 g/mL) to 100 L of a cellular suspen-
ion containing approximately 1 million cells per mil-
iliter and incubated for 30 minutes at 4°C in the dark.
econdary antibodies used were streptavidin-phyco-
rythrin (SAPE; Caltag, Burlingame, CA), goat anti-
ouse IgG1-FITC (Southern Biotechnology Associ-
tes, Birmingham, AL), and goat anti-rabbit/PE
Caltag). They were added (1 g/mL) after 1 wash,
nd the incubation was identical. After a last wash, the
ells were resuspended in HBSS/2% heat-inactivated
orse serum supplemented with propidium iodide for
xcluding dead cells and were analyzed on a ﬂuores-
ence-activated Flow Cytometer (Becton Dickinson,
an Jose, CA).
To determine the number of T cells in the circu-
ation (cells per microliter), the white blood cell count
as multiplied by the percentage of T cells deter-
ined by ﬂow cytometry. The speciﬁcity of the ATG
atch was assessed by staining blood from healthy
onors with ATG itself or with serum from an ATG-
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Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine HCT
Breated dog. T cells were detected with CD3 staining,
nd cell-bound ATG with goat anti-rabbit-PE. Nor-
al rabbit IgG (DAKO, Glostrup, Denmark) was
sed as a negative control.
ixed Leukocyte Reactions
PBMCs from 2 DLA-mismatched unrelated dogs
ere used as responder and stimulator cells [21].
BMCs were resuspended in Waymouth-Iscove me-
ium supplemented with 10% heat-inactivated,
ooled, normal dog serum, 1% nonessential amino
cids, 1% sodium pyruvate, and 2% l-glutamine. Both
 105 responder cells per well and 1 105 irradiated
25 Gy) stimulator cells per well were cocultured in
uintuplicate in round-bottomed 96-well plates for 6
ays at 37°C in a humidiﬁed 6% CO2 air atmosphere.
erial dilutions of ATG or sera from ATG-treated
ogs were added to the mixed leukocyte reactions
MLR). Final ATG concentrations ranged from 0 to
1 g/mL. Normal rabbit IgG was used as a negative
ontrol. On day 6, cultures were pulsed with 1 Ci
0.037 MBq) of 3H-thymidine for 18 hours before
arvesting. 3H-Thymidine uptake was measured as
he mean counts per minute of the 5 replicates by
sing a -scintillation counter (Packard BioScience,
eriden, CT).
TG Serum Levels, Anti-rabbit Antibody, and
nti-dog IgG Titers
An enzyme-linked immunosorbent assay was used
o measure serum ATG levels [22]. Brieﬂy, 96-well
olyvinyl plates were coated with goat anti-rabbit IgG
DAKO), blocked with 5% nonfat milk in phosphate-
uffered saline, and incubated with serum from the
reated dogs, diluted 1:500. Bound ATG was detected
y horseradish peroxidase–conjugated goat anti-rab-
it IgG (HL; Pierce, Rockford, IL) as the secondary
ntibody. The color reagent was 2,2=-azino-bis (3-
thylbenzthiazoline-6-sulfonic acid) (Sigma, St. Louis,
O), and plates were read with a Vmax microtiter
late reader (Molecular Devices, Menlo Park, CA) at
05 nm. Standard curves were established with known
oncentrations of ATG, and sera from dogs before
nfusion served as controls. A similar procedure was
sed to detect anti-rabbit antibodies, except that plates
ere coated with diluted ATG, and bound antibodies
ere detected by horseradish peroxidase–conjugated
oat anti-dog IgM ( chain) or IgG (HL; ICN,
urora, OH) to distinguish between the 2 isotypes.
iters of anti-dog IgG within the ATG preparation
ere determined as follows: plates were coated with
ormal dog IgG (Jackson Immuno Research, West
rove, PA), and ATG was added in serial 1:2 dilu-
ions; bound antibodies were revealed with horserad-
sh peroxidase–conjugated goat anti-rabbit IgG, and
ormal rabbit IgG was used as a negative control. k
B & M Tssessment of Lymph Node Cellularity
Lymph node T cells were quantiﬁed in 2 dogs. In
ach, 1 popliteal lymph node was surgically sampled
efore and the contralateral lymph node was sampled
fter ATG administration. Half of the specimen was
xed and embedded in parafﬁn. Sections were stained
ith hematoxylin-eosin or anti-human CD3 antibody
DAKO) speciﬁc to the intracytoplasmic portion of
he CD3 chain and highly cross-reactive with the
anine molecule. The remaining half of the node was
eighed, minced in RPMI 1640 with 2% fetal calf
erum, and ﬁltered to eliminate macroscopic debris.
he total number of cells present in the ﬁnal suspen-
ion was determined and, by using CD3 staining and
ow cytometry analysis, the number of T cells per
ram of lymph node tissue was calculated.
mmune Function Study
In 2 additional dogs, we assessed the immune
esponses to rabbit ATG, as well as to sheep red blood
ells (SRBCs; Research Diagnostics Inc., Flanders,
J) as a control immunogen. Methotrexate (MTX)
as given for additional immunosuppression to inhibit
he production of canine anti-rabbit antibodies. Two
ogs received ATG (1 mg/kg/d) from days 0 to 4 and
dose of MTX (0.4 mg/kg IV) on day 2 or day 9.
RBCs, 1 mL of a 10% suspension, were given IV on
ay 0. Sera were collected for up to 6 weeks, and
emagglutinin titers, [23] as well as dog anti-rabbit
ntibody titers, were measured.
kin Grafting
The surgical and biopsy protocols have been pre-
iously described [24]. Skin grafts were performed
etween DLA-mismatched unrelated dogs. ATG was
iven to recipients at 1 mg/kg on day 2 and 0.5 mg/
g/d from day 1 to day 20 after skin grafting.
nrelated and autologous control skin grafts were
ransplanted simultaneously. After removal of dress-
ngs on day 7, skin grafts were examined daily for signs
f inﬂammation. The day of rejection was determined
y the occurrence of erythema, edema, and epidermal
eactions and was conﬁrmed in all cases by histology,
ith particular attention to cellular inﬁltrates and dis-
orted epidermal architecture.
ematopoietic Cell Transplantation
Recipients were administered 1 Gy of TBI at
cGy/min from a high-energy linear accelerator
CLINAC 4; Varian, Palo Alto, CA). Marrow was
spirated from donors under general anesthesia
hrough long needles inserted into the humeri and
ere infused IV within hours of TBI. Marrow grafts
ontained 175 to 453  106 total nucleated cells per
ilogram (median, 263  106 total nucleated cells per
337
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3ilogram), 4.1 to 11.3  106 CD34 cells per kilogram
median, 6.6  106 CD34 cells per kilogram), and 6.9
o 38.5 106 CD3 cells per kilogram (median, 17.8
06 CD3 cells per kilogram; Table 1). All dogs re-
eived standard postgrafting care. Immunosuppres-
ion consisted of CSP 15 mg/kg twice a day orally
rom day 1 to day 35, combined with MMF 10
g/kg twice a day SQ from day 0 to day 27. CSP
evels were measured at least weekly, and results were
sed for CSP dose adjustments; MMF doses were
djusted according to clinical toxicity.
ssessment of Chimerism
Hematopoietic engraftment was assessed by doc-
mentation of donor dinucleotide and tetranucleotide
ariable number tandem repeat (VNTR) polymor-
hisms in cells from peripheral blood and marrow by
sing a polymerase chain reaction (PCR)–based assay
s previously described [25]. Samples were drawn
eekly for 3 months and then every 2 weeks. Granu-
ocyte and mononuclear cell (MNC) fractions were
solated from blood by Ficoll gradient centrifugation
speciﬁc gravity, 1.074), and DNA was extracted. Chi-
erism was also assessed at least once in unfraction-
ted marrow samples and among circulating T cells,
orted by ﬂuorescence-activated cell sorting. PCR am-
liﬁcation with informative radioactively labeled
NTR primers was performed [1]. PCR products
ere analyzed by gel electrophoresis, and percentages
f donor chimerism in the recipients were determined
y visual approximation after autoradiography.
tatistical Analysis
Responses between ATG-treated MLR cultures
nd controls were compared by using a Wilcoxon
ank-sum test. The median duration of mixed chimer-
sm was estimated with the Kaplan-Meier method.
he duration of mixed chimerism was compared with
hat of 6 historical controls [1] by using the log-rank
est. The association between cell doses in the grafts
nd the mixed chimerism duration was evaluated with
he Spearman rank correlation coefﬁcient. All re-
orted P values were 2 sided, and those .05 were
onsidered signiﬁcant.
able 1. Marrow Grafts from DLA-Identical Donors after ATG and 1
Dog
No.
ATG
(mg/kg)
Marrow Cells (million/kg)
TNC CD34 CD
200 3.5 263 4.2 17
198 4 345 4.1 25
166 5 206 7.5 6
208 4 453 11.3 38
252 4 175 6.6 13
LA indicates dog leukocyte antigen; ATG, antithymocyte glob
mononuclear cells.
38ESULTS
n Vitro Studies, Pharmacokinetics, Lymphocyte
hanges, and Skin Grafts in Healthy Dogs
ATG speciﬁcity. White blood cells from a healthy
og were incubated with the ATG preparation at a
oncentration of 4 g/mL (Figure 1) and with sera
rom a dog that had received a cumulative dose of
mg/kg ATG SQ. Sera were drawn before ATG and
n days 5 and 8 after the ﬁrst ATG injection. Serum
TG levels at those time points were 0, 37, and
7 g/mL, respectively. Figure 1 shows that ATG
ound to all white blood cells. However, ATG had
ore binding afﬁnity for CD3 cells, as the ﬂuores-
ence intensity of their staining (double-positive cells)
as approximately 1 log higher than that of CD3
ells (PE-positive, FITC-negative cells). The ATG
reparation also contained antibodies that cross-re-
cted with canine IgG at a titer of 1:4096.
Mixed leukocyte reactivity. ATG at 4 different con-
entrations ranging from 0.5 to 10 g/mL or normal
abbit IgG (negative control) was added to the MLR
ithout complement (Figure 2). Thymidine uptake
as signiﬁcantly decreased at low ATG concentra-
ions (0.5-5 g/mL; P  .01) but was unchanged at
he highest concentration of 10 g/mL (P  .92).
Pharmacokinetic studies. Five dogs were adminis-
ered ATG in a dose-ﬁnding approach; they did not
eceive marrow grafts. The ﬁrst dog received ATG
mg/kg IV once a day for 2 consecutive days; this was
ssociated with severe side effects that resembled sep-
ic shock. Thereafter, the SQ route was used in 4
dditional dogs. They received ATG 0.5 to 1 mg/kg
nce a day for cumulative doses ranging from 2 to
mg/kg. No premedication was used, and no side
ffects were seen.
Serum levels of ATG in the 5 dogs peaked at 6 to
2 g/mL on days 4 to 6, proportional to the total
oses administered, and became undetectable by day
3 in all cases. Figure 3 shows the ATG serum levels
nd the total peripheral blood lymphocyte and CD3
-cell counts for 2 dogs given cumulative doses of 3.5
nd 5 mg/kg.
TBI Delivered at 7 cGy/min
Maximum Donor
MNC Chimerism
(%)
Graft
Rejection
Engraftment
Duration
(wk)
5 Yes 8
25 Yes 18
25 Yes 11
40 No >36
5 Yes 8
BI, total body irradiation; TNC, total nucleated cells; MNC,Gy of
3
.8
.1
.9
.5
.2
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BEffect of ATG on lymphocytes. The baseline periph-
ral blood CD3 T-cell counts were 1240 to 2100/L.
fter ATG administration, T-cell counts declined in
ll 5 dogs, reaching nadirs of 90 to 220/L, concur-
ent with the peak of serum ATG (Figure 3). CD4
nd CD8 T cells were reduced equally. Peripheral
lood B cells were reduced to a lesser extent. Neutro-
hils, platelets, and red blood cells were not affected
data not shown).
We observed a dose-dependent effect of ATG on
cells. Lymph node biopsies in the dogs that received
TG 2 mg/kg showed approximately 50% T-cell de-
letion on days 5 and 9 compared with baseline, as
ssessed by ﬂow cytometry and morphology (Figure 4).
heir peripheral blood showed T-cell nadirs of 160
nd 220 cells per microliter, or 9% and 18% of base-
ine levels, respectively. On the basis of these ﬁndings,
TG doses of 3.5 to 5 mg/kg were used for HCT, and
hey resulted in T-cell nadirs of approximately 5% of
aseline, or 100 cells per microliter.
Skin grafts. Five dogs were given ATG and skin
ransplants from DLA-mismatched unrelated donors
o assess the immunosuppressive properties of the
TG batch. They rejected the grafts after a median of
4 days (range, 13-17 days). This was signiﬁcantly
onger than historical and concurrent controls not
iven ATG (n  28), which rejected unrelated skin
rafts after a median of 8 days (range, 7-9 days) [23,24]
P  .003; Wilcoxon rank-sum test). Autologous skin
igure 1. Staining of normal white blood cells with (a) ATG diluted
t baseline and on days 5 and 8 after ATG administration.rafts survived indeﬁnitely. q
B & M Tematopoietic Cell Transplantation
Five dogs were given HCTs from DLA-identical
onors, which were either littermates (n  4) or sib-
ings from another litter (n  1). TBI 1 Gy and
arrow infusion were given on day 0. ATG was ad-
inistered between days 12 and 7 at cumulative
oses of 3.5 to 5 mg/kg (median, 4 mg/kg; Table 1).
erum ATG levels peaked at 31 to 46 g/mL (median,
7 g/mL) and became undetectable by day 0. CD3
ells reached pretransplantation nadirs of 24 to 205
ells per microliter (median, 134 cells per microliter).
g/mL; and (b-d) sera from a dog treated with ATG 4 mg/kg, drawn
igure 2. MLR assays using MNCs from DLA-mismatched unre-
ated dogs. ATG at concentrations from 0.5 to 10 g/mL or normal
abbit IgG (RIG), as a negative control, was added to the reactions.
H-Thymidine uptake is shown as average counts per minute fromat 4 uintuplicate assays. P values are in reference to rabbit IgG.
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3nder ATG therapy, T-lymphocyte counts declined
rom a median of approximately 3000/L to 200/L,
nd there was also a decline in median platelet counts
rom 300 000/L to 120 000/L. After TBI, T-lym-
hocyte counts remained 1000/L for 5 weeks be-
ore returning to pre-ATG levels. The median abso-
ute neutrophil count ranged from 2000/L to
000/L throughout the ﬁrst 4 weeks after transplan-
ation before returning to the reference range. Platelet
ounts nadired on day 14 at a level of approximately
0 000/L before full recovery.
Engraftment. All 5 dogs showed prompt initial
ngraftment. The donor chimerism levels reached
eaks of 10% to 75% (median, 25%) for granulocytes
nd 5% to 40% (median, 25%) for MNCs just after
ostgrafting immunosuppression was discontinued
week 5; Figure 5, A and B). Four of the 5 dogs
ejected their grafts 8 to 18 weeks after HCT without
vidence of cytopenias. The ﬁfth dog has remained a
ixed chimera at 	36 weeks of follow-up, with donor
ontributions of 1% for granulocytes and 25% for
NCs. The median durations of engraftment in the 5
ogs (11 weeks) were similar to those among 6 histor-
cal controls [1] not given ATG (median, 10 weeks;
 .20; log-rank test).
Transplant-related toxicities. Hematologic toxicity
as generally mild (Figure 5C). There were no neu-
ropenias and no episodes of infections. Thrombocy-
igure 3. Pharmacokinetic studies in nontransplanted dogs: ATG
dministration, peripheral blood ATG levels, and total lymphocyte
nd CD3 T-cell counts in 2 healthy dogs given cumulative ATG
oses of 3.5 mg/kg (A) and 5 mg/kg (B).openias were moderate, with median platelet nadirs C
40f 33  109/L on day 13. Only 1 dog (G200) experi-
nced severe thrombocytopenia (nadir, 8  109/L)
nd required transfusions. T cells reached a ﬁrst nadir
n day 7 and a second nadir around day 10. Their
ecoveries started after discontinuation of immuno-
uppression (week 5) and reached pre-ATG values
round week 7 after HCT. The T-cell changes in the
dogs with rejection were similar to those in dog
208, which had sustained engraftment. The main
onhematologic toxicity was gastrointestinal and in-
luded transient anorexia, weight loss, and diarrhea,
ost likely due to MMF. Graft-versus-host disease
as not observed.
Marrow cell doses and chimerism. Table 1 shows that
he dog with sustained engraftment (G208) had re-
eived the largest marrow cell dose. Analysis of total
ucleated cells and CD34 and CD3 cell doses admin-
stered showed that the total nucleated cell dose did
ot have a statistically signiﬁcant Spearman correla-
ion coefﬁcient with the duration of engraftment
0.82; P  0.09).
igure 4. Lymph node immunohistochemistry for T cells using
D3 staining (dark areas) before (A) and after (B) ATG 2 mg/kg.
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Banine Anti-ATG Antibody Responses
Prompted by the observation of a shorter-than-
nticipated ATG half-life, antibody responses to ATG
ere measured in dogs given either skin grafts (n  3)
r HCT (n  5; Figure 6). Antibodies to rabbit ATG
egan to appear 6 to 7 days after the ﬁrst ATG dose,
nd their titers increased as ATG was cleared from the
irculation. The hosts’ immune responses were pre-
ominantly of the IgG isotype, as these titers were
igniﬁcantly higher than the IgM antibodies. Of note,
n the skin-grafted animals, the ATG levels peaked on
ay 8 and decreased afterward through antibody neu-
ralization, becoming almost undetectable after day
4, even though ATG was scheduled to be adminis-
ered until day 22. In the HCT recipients, the anti-
abbit IgG contributed to ATG clearance by day 0.
This observation prompted us to study immune
esponses to ATG and SRBCs in 2 additional dogs.
mmunosuppression with MTX was administered af-
er ATG to abrogate the production of canine anti-
odies. MTX did not change the immune response to
TG compared with the previous dogs that received
TG alone; anti-rabbit ATG antibodies appeared 6 to
days after the ﬁrst ATG dose and consisted mostly of
gG antibodies. However, neither of the 2 dogs
igure 5.Donor chimerism levels in the granulocyte (A) and MNC
B) fractions and (C) median peripheral blood changes in 5 dogs
iven ATG and 1 Gy of TBI before and MMF/CSP after marrow
rafts from DLA-identical donors.howed detectable antibody responses to SRBCs, 
B & M Thich were used as a control neoantigen (data not
hown).
ISCUSSION
Marrow grafts between DLA-identical canine lit-
ermates have been almost uniformly successful after
onditioning with the sublethal dose of 2 Gy of TBI
hen recipients were given postgrafting immunosup-
ression with MMF/CSP. This regimen has been suc-
essfully translated into the clinic to treat human pa-
ients with malignant and nonmalignant hematologic
iseases [2-4]. However, engraftment in dogs after
nly 1 Gy of TBI was uniformly transient; this sug-
ests a delicate immunologic balance. Results from
reviously published TBI dose de-escalation studies
26,27] have allowed us to estimate the residual host
-cell populations in dogs given 2 and 1 Gy of TBI to
e 10% and 35%, respectively (Schwartz and Storb,
npublished data, 2005).
This study was undertaken under the assumption
hat pretransplantation ATG would reduce host T-
ell numbers in a manner equivalent to 1 Gy of TBI.
e were concerned, however, that residual ATG
ight adversely affect the grafted donor T cells and,
hereby, impair engraftment.
That concern turned out to be unfounded be-
ause, surprisingly, recipient dogs mounted IgG anti-
igure 6. ATG levels and canine antibody production to rabbit
TG in recipients of (A) skin grafts (n  3) and (B) HCT (n  5).
ays of ATG administration were 0 to 22 in (A) and between day
12 and 7 in (B).
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3TG antibody responses that promptly cleared the
gent from the circulation by the time of HCT. De-
pite this and despite the profound lymphocytopenia
nd lymph node depletion of T cells, most trans-
lanted dogs eventually rejected their grafts after ex-
ended periods of mixed donor/host chimerism. This
esult was not signiﬁcantly different from that in dogs
onditioned with 1 Gy of TBI but without ATG.
How can we explain the current failure of sus-
ained engraftment in 4 of the 5 dogs studied? In all
ikelihood, the T-cell depletion achieved with rabbit
TG was insufﬁcient. If we assume the estimates of
-cell depletion by 1 and 2 Gy of TBI, respectively, to
e correct, then 10% of residual host T cells favored
ustained engraftment in this model, whereas 35% of
ost T cells did not. Assuming, next, a reduction of
ost T cells by rabbit ATG of 50%, the combination
f pretransplantation ATG and 1 Gy of TBI should
esult in an estimated residual host T-cell population
f approximately 17%. Thus, ATG plus 1 Gy of TBI
ell short of the 10% residual host T cells estimated
or 2 Gy of TBI, which permitted sustained engraft-
ent in 11 of 12 dogs studied. It was not clear why 1
f the 5 dogs showed sustained engraftment, although
possible explanation might be fortuitous matching
or a more important minor histocompatibility locus.
t present, we are unable to determine minor histo-
ompatibility antigens by in vitro tests.
Other characteristics of the ATG preparation
ould have interfered with its immunosuppressive ef-
ects. For example, the inhibitory in vitro effect in
LRs was lost at higher ATG concentrations. This
ight have been due to the presence in ATG of
ntibodies with mitogenic activity (directed to CD2
nd CD3), [9] the relatively high content of endotoxin
4.9 endotoxin units per milligram of IgG), or both.
Besides immunosuppression, other important
omponents of HCT are the quantity and composi-
ion of the hematopoietic cells administered. Success-
ul engraftment after 1 Gy of TBI was achieved in this
odel when marrow transplants were combined with
ranulocyte colony-stimulating factor–mobilized do-
or PBMCs [18]. In this analysis, larger total nucle-
ted cell numbers showed a trend toward a longer
uration of engraftment, and this suggests that mar-
ow cells might facilitate their own engraftment in a
ose-dependent manner and through a similar mech-
nism. In clinical HCT studies using myeloablative
egimens and marrow transplantation from related
28] or unrelated [29] donors, larger total nucleated
ell doses were associated with better leukemia-free
urvival.
The pharmacokinetic studies revealed that ATG
as cleared from the circulation by neutralizing anti-
odies within 13 days. This is very similar to obser-
ations in a nonhuman primate model [22]. In clinical
tudies of HCT, [30-32] ATG persisted for more than J
420 to 100 days after transplantation. Human patients
iven HCT are often immunosuppressed from prior
hemotherapy. Therefore, humoral antibody produc-
ion might be impaired in comparison to healthy ex-
erimental animals, and this might explain the longer
alf-life of ATG in the clinical reports.
The antibody response to ATG had the charac-
eristics of a secondary immune response, not only
ecause of its rapid kinetics, but also because of the
roduction of antibodies of the IgG isotype. The
atter observation is corroborated by 2 other studies
22,31] in which the hosts produced anti-ATG anti-
odies of the IgG isotype. Dogs in the present study
ere exposed to ATG for the ﬁrst time; however, they
ounted secondary immune responses. To reconcile
hese 2 facts, we propose the following explanation: as
hown, ATG contained rabbit antibodies that cross-
eacted with canine IgG. IgG is also found in mem-
rane-bound form in the B-cell antigen receptor
mIgG-BCR). It is possible that ATG cross-reacted
ith the mIgG-BCR and triggered B cells through
his very effective signaling pathway, leading to their
ctivation and proliferation and to efﬁcient produc-
ion of IgG antibodies [33], which, in turn, might have
TG complementarities and might lead to neutraliza-
ion and clearance of ATG.
This hypothesis was indirectly supported by the
bservations made in 2 dogs that received MTX in an
ttempt to suppress the anti-ATG immune responses.
heir antibody responses to the neoantigen, SRBC,
ere completely suppressed; however, the magnitudes
f their antibody responses to ATG were comparable
o those seen in the 8 previous dogs. This is consistent
ith secondary immune responses that were not af-
ected by MTX.
In conclusion, rabbit ATG produced an estimated
0% T-cell depletion in dogs; however, this degree of
-cell depletion was not sufﬁcient to compensate for
he deletion of 1 Gy of TBI conditioning, and all dogs
ut 1 eventually rejected their marrow grafts. ATG
riggered a strong immune response in immunocom-
etent hosts, and this resulted in its rapid clearance
rom circulation.
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